

Company name: Neuralight Website: [www.neuralight.ai](http://www.neuralight.ai) CEO name: Edmund Ben-Ami

Category: Health IT / Digital Suggested session: Reinventing Clinical Trials: New Models, Technologies, and Companies Executive Summary Neuralight provides the measurement layer for precision neurology, a \$100B+ opportunity across drug development, clinical care, and preventive brain health. Neuralight's functional biomarker assay accurately quantifies neurological decline, disease progression, and treatment response. Validated to outperform gold-standard clinical scales in multiple clinical indications in neurology, we're actively partnering in drug trials across PD, ALS, HD, PSP, and more. Core Technology Neuralight's core technology is a software-based platform that extracts biomarkers from short, designated visual tasks, measuring function across key brain regions. While neurology still relies on subjective, symptom-based rating scales as the gold-standard for tracking change over time, Neuralight's biomarkers are the only ones validated to outperform these scales, enabling reliable treatment-effect quantification in shorter, smaller clinical trials. Product Roadmap Neuralight is active in drug-trial partnerships across PD, ALS, HD, PSP, MS, and expanding to additional indications. We address a \$25B near-term pharma biomarker market by helping biopharma companies quantify treatment effect and identify responders. As early programs conclude, our next milestones will convert clinical validation into commercial proof points, demonstrating value for our partners in their drug development programs. Business Strategy Neuralight's strategy is to scale first through pharma drug trials, generating near-term revenue, additional clinical validation, and stakeholders' adoption. Partnering in these drug trials creates the pathway into clinics, where the same biomarker platform can expand from drug development into patient monitoring, preventive brain health, and approved next-generation neurology drugs. What's Next Neuralight's next phase is about growth: keep scaling fast in pharma trials, increase revenue, and use trial deployments to enter leading neurology clinics. Ahead of the next funding round, we will keep scaling pharma trials, increase revenue and generate a preventative health go-to-market motion, establishing Neuralight as a prominent infrastructure for the future of brain health